Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bempedoic acid + ezetimibe + high-intensity statin for coronary atherosclerosis plaque regression
2025-524625-41-00Phase 3Authorised
- Sponsor
- Daiichi Sankyo
- Start
- Jul 2026
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 3
01
Overview
Phase 3, single-arm trial of bempedoic acid, ezetimibe, atorvastatin, rosuvastatin and bempedoic acid + ezetimibe in coronary arteriosclerosis, sponsored by Daiichi Sankyo. Primary endpoint: Annualised change in percentage plaque burden at End of Treatment. Planned start Jul 2026; status: authorised.
02
Drugs
bempedoic acidezetimibeatorvastatinrosuvastatinbempedoic acid + ezetimibe
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on 2025-524625-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524625-41-00.